Johnson & Johnson said it expects its sales growth to slow in 2019, citing pricing pressures and generic-drug competition for its pharmaceutical division. The health-products company, whose financial results are considered a bellwether for many health sectors, said Tuesday it expects full-year sales of $80.4 billion to $81.2 billion. For 2018, J&J said its sales rose 6.7% to $81.6 billion.

Source: Wall Street Journal January 22, 2019 12:33 UTC